Abstract: A device for aligning light-emitting diodes (LEDs) by using a carrier substrate is provided. The carrier substrate defines a plurality of positioning grooves, and each positioning groove is configured for accommodating one of the LEDs. The device includes a carrying part for carrying the carrier substrate, a vibration part connected to the carrying part and for vibrating the carrier substrate, and a magnetic generator on a side of the carrier substrate away from the positioning grooves. A method for aligning LEDs is also provided.

Abstract: Acute myelogenous leukaemia (AML) often bear a mutation in the NPM1 nucleolar chaperone, but the transforming properties of the NPM1c oncoprotein remain incompletely understood. Here the inventors show that NPM1c binding to PML, a key senescence gene, disrupts PML nuclear bodies (NB) yielding proliferation, mitochondrial alterations and intracellular stress. Actinomycin-D (ActD), an anticancer antibiotic with clinical efficacy in NPM1c-AMLs, targets these dysfunctional mitochondria to induce ROS. The later disrupt disulphide-linked NPM1c/PML complex, restoring PML NBs and initiating senescence. An ActD-responsive patient displayed features of mitochondria-initiated senescence. These studies highlight unexpected mitochondrial involvement both downstream of the NPM1c/PML axis and as a key feature of ActD therapy.

Abstract: A nucleic acid detection kit includes a detection chip, an electrophoresis box, and a connection unit. The detection chip includes interconnected channel, outlet, and first opening. The electrophoresis box is disposed below the detection chip. The electrophoresis box includes an inlet corresponding to the channel and a second opening away from the channel. The outlet is connected to the inlet. One end of the connection unit is connected to the first opening, and the other end is connected to the second opening, so that the channel is further connected to the electrophoresis box for pressure equalization during transportation and sudden movements. A nucleic acid detection device able to receive the nucleic acid detection kit is also disclosed.

Abstract: A method for treating and/or alleviating nervous diseases is provided. The method for treating and/or alleviating nervous diseases includes: administering an effective amount of a water extract of a plant of Gracilariaceae or a ferment thereof to a subject in need thereof to treat and/or alleviate a nervous disease thereof, wherein the ferment of the water extract of a plant of Gracilariaceae is a lactic acid bacteria ferment.

Abstract: The present disclosure provides a method for treating and/or alleviating nervous diseases, including: administering an effective amount of a water extract of a plant of Gracilariaceae or a ferment thereof to a subject in need thereof to treat and/or alleviate a nervous disease thereof, wherein the ferment of the water extract of a plant of Gracilariaceae is a lactic acid bacteria ferment.

Abstract: The present disclosure provides a method for treating and/or alleviating nervous diseases, including: administering an effective amount of a water extract of a plant of Gracilariaceae or a ferment thereof to a subject in need thereof to treat and/or alleviate a nervous disease thereof, wherein the ferment of the water extract of a plant of Gracilariaceae is a lactic acid bacteria ferment.

Abstract: An optical connector includes a substrate, plural optical channels for transmitting an optical signal, a light source, an oblique structure, and a photo detector. The light source is located on the substrate to emit a first optical signal. The oblique structure has an optical reflective surface to reflect the first optical signal emitted by the light source to at least one of the optical channels. The photo detector is located on the substrate to receive a second optical signal emitted by at least one of the optical channels. The optical reflective surface has at least one gap, such that the optical reflective surface is divided into at least two segments by the gap, and the segments are not electrically connected with each other.

Abstract: An optical connector includes a substrate, plural optical channels for transmitting an optical signal, a light source, an oblique structure, and a photo detector. The light source is located on the substrate to emit a first optical signal. The oblique structure has an optical reflective surface to reflect the first optical signal emitted by the light source to at least one of the optical channels. The photo detector is located on the substrate to receive a second optical signal emitted by at least one of the optical channels. The optical reflective surface has at least one gap, such that the optical reflective surface is divided into at least two segments by the gap, and the segments are not electrically connected with each other.

Abstract: The disclosure provides a pharmaceutical composition for inhibiting angiogenesis, including an effective amount of an extract of Juniperus chinensis or an effective amount of a lignan as an effective ingredient. The pharmaceutical composition may further include a pharmaceutically acceptable carrier or salt. The disclosure also provides a method for inhibiting angiogenesis, including administering an effective amount of an extract of Juniperus chinensis or an effective amount of a lignan as an effective ingredient for inhibiting angiogenesis to a subject in need thereof.

Abstract: The disclosure provides a method for modulating Th17 cells, including: administering an Antrodia cinnamomea (also named Antrodia camphorata or Taiwanofungus camphoratus) extract to a subject in need thereof, wherein the Antrodia cinnamomea extract has an effect of modulating Th17 cells. The Antrodia cinnamomea extract may include a fruiting body extract of Antrodia cinnamomea or a mycelium extract of Antrodia cinnamomea.

Abstract: The disclosure provides a pharmaceutical composition for inhibiting angiogenesis, including an effective amount of a lignan as an effective ingredient. The pharmaceutical composition may further include a pharmaceutically acceptable carrier or salt. The disclosure also provides a method for inhibiting angiogenesis, including administering an effective amount of a lignan as an effective ingredient for inhibiting angiogenesis to a subject in need thereof.

Abstract: The disclosure provides a method for modulating Th17 cells, including: administering an Antrodia cinnamomea (also named Antrodia camphorata or Taiwanofungus camphoratus) extract to a subject in need thereof, wherein the Antrodia cinnamomea extract has an effect of modulating Th17 cells. The Antrodia cinnamomea extract may include a fruiting body extract of Antrodia cinnamomea or a mycelium extract of Antrodia cinnamomea.

Abstract: The disclosure provides a pharmaceutical composition for inhibiting angiogenesis, including an effective amount of an extract of Juniperus chinensis or an effective amount of a lignan as an effective ingredient. The pharmaceutical composition may further include a pharmaceutically acceptable carrier or salt. The disclosure also provides a method for inhibiting angiogenesis, including administering an effective amount of an extract of Juniperus chinensis or an effective amount of a lignan as an effective ingredient for inhibiting angiogenesis to a subject in need thereof.

Abstract: The disclosure provides a vaccine adjuvant, including a polysaccharide derived from Antrodia camphorata (also named Antrodia cinnamomea or Taiwanofungus camphoratus) fruiting body, wherein the molecular weight of the polysaccharide is greater than 100 K Da. Furthermore, the polysaccharide is obtained by an extraction process, and the extraction process includes: (a) adding powder of the Antrodia camphorata fruiting body into water to form a mixture; (b) heating the mixture under reflux; (c) after step (b), removing an insoluble matter from the mixture; (d) after step (c), adding ethanol into the mixture to perform a precipitating step and obtain a precipitate; and (e) performing an isolating step to the precipitate to obtain a fraction the molecular weight of which is greater than 100 K Da of the precipitate.

Abstract: The present invention discloses a vehicle control system including a vehicle parameter storage device and a vehicle computer device. The vehicle storage device includes a memory module for storing vehicle parameter information, and a parameter transmission interface couple to the memory module for transmitting the vehicle parameter information. The vehicle computer device is installed inside a vehicle for controlling operation of the vehicle. The vehicle computer device includes a datum transmission interface for electrically connecting to the parameter transmission interface so as to transmit the vehicle parameter information with the parameter transmission interface, and a control module electrically connected to the datum transmission interface for controlling the operation of the vehicle according the vehicle parameter information transmitted from the datum transmission interface.

Abstract: Pharmaceutical compositions for treating immunological disorders and the preparing method of the same are disclosed, which include alcohol extracts of Radix Dioscorea, Rhizoma Alismatis, Poria cocos (schw) Wolf, and Scutellaria Baicalensis. The compositions are manufactured by novel procedures consisting of decocting using specific concentration ranges of alcohol, filtering, regulating pH value, purifying, concentrating, proportionally mixing, and making a granule powder from lyophilized extract. This invention used both in vitro and in vivo assays to evaluate therapeutic effects of specific combination of herbal plant extracts. The combination of herbal extracts has been able to maximize the anti-inflammatory activity and regulate the secretion of cytokines such as eotaxin and IL-4.

Abstract: Pharmaceutical compositions for treating immunological disorders and the preparing method of the same are disclosed, which include alcohol extracts of Radix Dioscorea, Rhizoma Alismatis, Poria cocos (schw) Wolf, and Scutellaria Baicalensis. The compositions are manufactured by novel procedures consisting of decocting using specific concentration ranges of alcohol, filtering, regulating pH value, purifying, concentrating, proportionally mixing, and making a granule powder from lyophilized extract. This invention used both in vitro and in vivo assays to evaluate therapeutic effects of specific combination of herbal plant extracts. The combination of herbal extracts has been able to maximize the anti-inflammatory activity and regulate the secretion of cytokines such as eotaxin and IL-4.